Phage therapy: Targeting intestinal bacterial microbiota for the treatment of liver diseases

JHEP Rep. 2023 Sep 23;5(12):100909. doi: 10.1016/j.jhepr.2023.100909. eCollection 2023 Dec.

Abstract

Phage therapy has been overshadowed by antibiotics for decades. However, it is being revisited as a powerful approach against antimicrobial-resistant bacteria. As bacterial microbiota have been mechanistically linked to gastrointestinal and liver diseases, precise editing of the gut microbiota via the selective bactericidal action of phages has prompted renewed interest in phage therapy. In this review, we summarise the basic virological properties of phages and the latest findings on the composition of the intestinal phageome and the changes associated with liver diseases. We also review preclinical and clinical studies assessing phage therapy for the treatment of gastrointestinal and liver diseases, as well as future prospects and challenges.

Keywords: Alcohol use disorder; Alcohol-associated hepatitis; Gut-liver-axis; Microbiome; NAFLD; NASH; PSC; Phageome; Virome.

Publication types

  • Review